Bioactive IGF-I Concentrations in Children on GH Therapy
Authors' conclusion
Bioactive IGF-I was within reference ranges in the majority of GH-treated children. Monitoring bioactive IGF-I may help optimize GH dosing in specific patient subgroups.
Study context
- Population
- Healthy children and adolescents (Copenhagen Puberty Study III) and short children on GH therapy with GH deficiency (GHD) or non-GHD conditions
- Participants
- 570 vs 126
- Exposure
- Bioactive IGF-I (KIRA) vs total IGF-I and IGF-I/IGFBP-3 molar ratio (iSYS) in healthy and GH-treated children
- Reference populationn = 570reference
- GH-treatedn = 126
- Outcome
- Bioactive and total IGF-I in healthy and GH-treated children and adolescents
Main finding
As reported in the abstract
Bioactive vs total IGF-I
- Correlation of bioactive IGF-I with total IGF-I, healthy males
- r = 0.61; P < .001
- Correlation of bioactive IGF-I with IGF-I/IGFBP-3, healthy males
- r = 0.57; P < .001
- Correlation of bioactive IGF-I with total IGF-I, healthy females
- r = 0.58; P < .001
- Correlation of bioactive IGF-I with IGF-I/IGFBP-3, healthy females
- r = 0.59; P < .001
- Correlation of bioactive IGF-I with IGF-I, BP-3 and acid labile subunit (liquid chromatography-tandem mass spectrometry)
- r = 0.56, r = 0.29, and r = 0.38; P < .001
- Correlation of bioactive IGF-I with IGF-II (negative)
- r = −0.29; P < .001
- GH-treated patients with bioactive IGF-I above +2SD
- 13% (17/126)
- GH-treated patients with total IGF-I above +2SD
- 25% (32/126)
- Patients with both total and bioactive IGF-I above +2SD
- Nine
- Non-GHD groups: bioactive IGF-I SDS lower than IGF-I SDS
- P = .015
Observational data: associations, not effects.
Original publication
Bioactive IGF-I Concentrations in Children on GH Therapy. J Clin Endocrinol Metab. Published 14 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →